Oncology and Hematology

Bringing Treatment Into Focus: Biomarker-Driven First-Line Therapy for Metastatic Gastric/GEJ Cancers

The Evolving Role of MET TKIs in NSCLC

Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer

Noncovalent BTK Inhibitors: New Targeted Options for Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

How Antibody-Based Therapies Are Revolutionizing Its Management

Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting

Patient Case: How Do HER2-Directed Therapies Fit Into the Biliary Tract Cancer Treatment Landscape?

Patient Case: How Do HER2-Directed Therapies Fit Into the Ovarian Cancer Treatment Landscape?

Monitoring and Managing Treatment-Related Adverse Effects Associated With HER2-Directed Agents

Emerging Data Evaluating HER2-Directed Therapies in Gynecologic Cancers

Pivotal Data on Targeting HER2 in HER2-Expressing Solid Tumors

Diversity in HER2 Expression Among Gynecologic Cancers

HER2 Testing Strategies Across Tumor Types Amidst Guidelines Gaps

Significance of HER2 Expression in Solid Tumors

The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies

Overcoming Disease Progression in CLL: Evidence-Based Re-treatment Considerations

Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting

Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk

MRD Testing to Guide Treatment Considerations in CLL